Literature DB >> 2239976

A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy.

C S Landefeld1, E McGuire, M W Rosenblatt.   

Abstract

PURPOSE: To construct and test prospectively a bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting long-term anticoagulant therapy. PATIENTS AND METHODS: In an inception cohort of 617 patients starting long-term anticoagulant therapy in one hospital, data were gathered retrospectively and bleeding was classified using reliable explicit criteria. We constructed a bleeding risk index by identifying and weighting independent predictors of major bleeding using a multivariate proportional-hazards model. The bleeding risk index was tested in 394 other patients prospectively identified in a second hospital. The index was compared to physicians' predictions.
RESULTS: Major bleeding developed before discharge in 61 of all 1,011 patients (6%). The bleeding risk index included four independent risk factors for major in-hospital bleeding: the number of specific comorbid conditions; heparin use in patients aged 60 years or older; maximal prothrombin or partial thromboplastin time 2.0 or more times control; liver dysfunction worsening during therapy. In the testing group, the index predicted major bleeding, which occurred in 3% of 235 low-risk patients, 16% of 96 middle-risk patients, and 19% of 63 high-risk patients (p less than 0.001). The bleeding risk index performed as well as physicians' predictions, and integration of the bleeding risk index with physicians' predictions led to a classification system that was more sensitive (p = 0.03) than physicians' predictions alone. In 86% of patients with a high risk of major bleeding, we identified specific ways of improving therapy, e.g., avoiding overanticoagulation and nonsteroidal anti-inflammatory agents.
CONCLUSION: The bleeding risk index provides valid estimates of the probability of major bleeding in hospitalized patients starting long-term anticoagulant therapy and complements physicians' predictions. The possibility that bleeding can be prevented in high-risk patients warrants prospective evaluation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2239976     DOI: 10.1016/0002-9343(90)90174-c

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  14 in total

Review 1.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Bleeding Risk Index in an anticoagulation clinic. Assessment by indication and implications for care.

Authors:  Sherrie L Aspinall; Beth E DeSanzo; Lauren E Trilli; Chester B Good
Journal:  J Gen Intern Med       Date:  2005-11       Impact factor: 5.128

Review 4.  Anticoagulants in older patients. A safety perspective.

Authors:  R J Beyth; C S Landefeld
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

5.  Evaluation of bleeding rates in renal transplant patients on therapeutic intravenous heparin.

Authors:  Theresa Ringenberg; Heather Desanto; Yekaterina Opsha; Jennifer Costello; Daryl Schiller
Journal:  Hosp Pharm       Date:  2013-12

6.  Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty.

Authors:  K M Akkerhuis; M J van Den Brand; C van Der Zwaan; H O Peels; H Suryapranata; L R van Der Wieken; J Stibbe; J Hoffmann; T Baardman; J W Deckers; M L Simoons
Journal:  Heart       Date:  2001-04       Impact factor: 5.994

Review 7.  Is the lung scan alive and well? Facts and controversies in defining the role of lung scintigraphy for the diagnosis of pulmonary embolism in the era of MDCT.

Authors:  John H Reid; Emmanuel E Coche; Tomio Inoue; Edmund E Kim; Maurizio Dondi; Naoyuki Watanabe; Giuliano Mariani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-27       Impact factor: 9.236

8.  Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study.

Authors:  Seth R Bauer; Narith N Ou; Benjamin J Dreesman; Jeffrey J Armon; Jan A Anderson; Stephen S Cha; Lance J Oyen
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

9.  Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage.

Authors:  Boris Leithäuser; Jai-Wun Park
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

Review 10.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.